Your browser doesn't support javascript.
loading
KMT2D loss drives aggressive tumor phenotypes in cutaneous squamous cell carcinoma.
Dauch, Cara; Shim, Sharon; Cole, Matthew Wyatt; Pollock, Nijole C; Beer, Abigail J; Ramroop, Johnny; Klee, Victoria; Allain, Dawn C; Shakya, Reena; Knoblaugh, Sue E; Kulewsky, Jesse; Toland, Amanda Ewart.
Afiliação
  • Dauch C; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine Columbus, OH 43210, USA.
  • Shim S; Central Michigan University College of Medicine Mount Pleasant, MI 48858, USA.
  • Cole MW; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine Columbus, OH 43210, USA.
  • Pollock NC; Department of Radiation Oncology, The Ohio State University Columbus, OH 43210, USA.
  • Beer AJ; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine Columbus, OH 43210, USA.
  • Ramroop J; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine Columbus, OH 43210, USA.
  • Klee V; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine Columbus, OH 43210, USA.
  • Allain DC; Department of Internal Medicine, Division of Human Genetics, The Ohio State University Columbus, OH 43210, USA.
  • Shakya R; Department of Internal Medicine, Division of Human Genetics, The Ohio State University Columbus, OH 43210, USA.
  • Knoblaugh SE; Comprehensive Cancer Center, The Ohio State University Columbus, OH 43210, USA.
  • Kulewsky J; Department of Veterinary Biosciences, The Ohio State University Columbus, OH 43210, USA.
  • Toland AE; Department of Pathology, The Ohio State University Wexner Medical Center Columbus, OH 43210, USA.
Am J Cancer Res ; 12(3): 1309-1322, 2022.
Article em En | MEDLINE | ID: mdl-35411237
Cutaneous squamous cell carcinoma (cSCC) is the second most lethal skin cancer. Due to ultraviolet light-induced damage, cSCCs have a high mutation rate, but some genes are more frequently mutated in aggressive cSCCs. Lysine-specific histone methyltransferase 2D (KMT2D) has a two-fold higher mutation frequency in metastatic cSCCs relative to primary non-metastatic associated cSCCs. The role of KMT2D in more aggressive phenotypes in cSCC is uncharacterized. Studies of other tumor types suggest that KMT2D acts to suppress tumor development. To determine whether KMT2D loss has an impact on tumor characteristics, we disrupted KMT2D in a cSCC cell line using CRISPR-cas9 and performed phenotypic analyses. KMT2D loss modestly increased cell proliferation and colony formation (1.4- and 1.6-fold respectively). Cells lacking KMT2D showed increased rates of migration and faster cell cycle progression. In xenograft models, tumors with KMT2D loss showed slight increases in mitotic indices. Collectively, these findings suggest that KMT2D loss-of-function mutations may promote more aggressive and invasive behaviors in cSCC, suggesting that KMT2D-related pathways could be targets for cancer therapies. Future studies to determine the downstream genes and mechanism of phenotypic effect are needed.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article